In the latest trading session, 0.89 million Moderna Inc (NASDAQ:MRNA) shares changed hands as the company’s beta touched 1.66. With the company’s most recent per share price at $53.01 changed hands at -$0.79 or -1.47% at last look, the market valuation stands at $20.38B. MRNA’s current price is a discount, trading about -221.58% off its 52-week high of $170.47. The share price had its 52-week low at $53.05, which suggests the last value was -0.08% down since then. When we look at Moderna Inc’s average trading volume, we note the 10-day average is 4.45 million shares, with the 3-month average coming to 4.91 million.

Analysts gave the Moderna Inc (MRNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.63. If we narrow down to specifics, the data shows that 2 out of 17 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended MRNA as a Hold, 12 felt it is a Buy and 0 rated the stock as Underweight. Moderna Inc’s EPS for the current quarter is expected to be -1.88.

Moderna Inc (NASDAQ:MRNA) trade information

Instantly MRNA was in red as seen in intraday trades today. With action -7.51%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -46.70%, with the 5-day performance at -7.51% in the red. However, in the 30-day time frame, Moderna Inc (NASDAQ:MRNA) is -17.36% down. Looking at the short shares, we see there were 31.32 million shares sold at short interest cover period of 5.03 days.

The consensus price target for the stock as assigned by Wall Street analysts is 145, meaning bulls need an upside of 63.44% from its recent market value. According to analyst projections, MRNA’s forecast low is 55 with 304 as the target high. To hit the forecast high, the stock’s price needs a -473.48% plunge from its current level, while the stock would need to soar -3.75% for it to hit the projected low.

Moderna Inc (MRNA) estimates and forecasts

Data shows that the Moderna Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -50.87% over the past 6 months, a 19.38% in annual growth rate that is considerably higher than the industry average of 17.20%. Year-over-year growth is forecast to reach -53.00% down from the last financial year.

Consensus estimates given by 15 financial analysts project the company’s revenue in the current quarter to hit an average of 1.22B. 15 analysts are of the opinion that Moderna Inc’s revenue for the current quarter will be 1.59B. The company’s revenue for the corresponding quarters a year ago was 1.83B and 2.81B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -33.30%. The estimates for the next quarter sales put growth at -43.30%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -20.02%. The 2024 estimates are for Moderna Inc earnings to increase by 21.56%.

MRNA Dividends

Moderna Inc is expected to release its next quarterly earnings report on 2024-Nov-07.

Moderna Inc (NASDAQ:MRNA)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 9.52% of Moderna Inc shares while 72.09% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 79.67%. There are 72.09% institutions holding the Moderna Inc stock share, with BAILLIE GIFFORD & CO the top institutional holder. As of 2024-06-30, the company held 11.3741% of the shares, roughly 43.45 million MRNA shares worth $5.16 billion.

VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 10.3568% or 39.56 million shares worth $4.7 billion as of 2024-06-30.